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A low resting heart rate (HR) would be of great benefit in cardiovascular diseases.
Ivabradine—a novel selective inhibitor of hyperpolarization-activated cyclic nucleotide
gated (HCN) channels- has emerged as a promising HR lowering drug. Its effects on
the autonomic HR control are little known. This study assessed the effects of chronic
treatment with ivabradine on the modulatory, reflex and tonic cardiovascular autonomic
control and on the renal sympathetic nerve activity (RSNA). Male Wistar rats were divided
in 2 groups, receiving intraperitoneal injections of vehicle (VEH) or ivabradine (IVA) during
7 or 8 consecutive days. Rats were submitted to vessels cannulation to perform arterial
blood pressure (AP) and HR recordings in freely moving rats. Time series of resting pulse
interval and systolic AP were used to measure cardiovascular variability parameters.
We also assessed the baroreflex, chemoreflex and the Bezold-Jarish reflex sensitivities.
To better evaluate the effects of ivabradine on the autonomic control of the heart, we
performed sympathetic and vagal autonomic blockade. As expected, ivabradine-treated
rats showed a lower resting (VEH: 362 ± 16 bpm vs. IVA: 260 ± 14 bpm, p = 0.0005)
and intrinsic HR (VEH: 369 ± 9 bpm vs. IVA: 326 ± 11 bpm, p = 0.0146). However, the
chronic treatment with ivabradine did not change normalized HR spectral parameters
LF (nu) (VEH: 24.2 ± 4.6 vs. IVA: 29.8 ± 6.4; p > 0.05); HF (nu) (VEH: 75.1 ± 3.7 vs.
IVA: 69.2 ± 5.8; p > 0.05), any cardiovascular reflexes, neither the tonic autonomic
control of the HR (tonic sympathovagal index; VEH: 0.91± 0.02 vs. IVA: 0.88 ± 0.03,
p = 0.3494). We performed the AP, HR and RSNA recordings in urethane-anesthetized
rats. The chronic treatment with ivabradine reduced the resting HR (VEH: 364 ± 12
bpm vs. IVA: 207 ± 11 bpm, p < 0.0001), without affecting RSNA (VEH: 117 ± 16
vs. IVA: 120 ± 9 spikes/s, p = 0.9100) and mean arterial pressure (VEH: 70 ± 4 vs.
IVA: 77 ± 6mmHg, p = 0.3293). Our results suggest that, in health rats, the long-term
treatment with ivabradine directly reduces the HRwithout changing the RSNAmodulation
and the reflex and tonic autonomic control of the heart.
Keywords: ivabradine, HCN channels, renal sympathetic nerve activity, cardiovascular reflexes, tonic control,
vagal activity, sympathetic activity
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INTRODUCTION
There is a clear association between increased resting heart rate
(rHR) and mortality rate, especially in patients suffering from
cardiovascular disease (Fox et al., 2008; Verrier and Tan, 2009).
It is noteworthy that this association is true not only for very
high values of rHR, since rHR upper than 83 bpm has been
associated with an increased risk for all-cause and cardiovascular
mortality (Diaz et al., 2005). From a physiological point of view,
rHR reduction promotes a bigger and better coronary perfusion
leading to a greater oxygen balance and cardiac performance.
Thus, a low rHR would be of great benefit for patients with
cardiovascular disease (i.e., heart failure and angina pectoris)
(Hall and Palmer, 2008; Gent et al., 2015).
Beta-adrenoceptors antagonists have been used for reducing
heart rate. They are indicated as first-line therapy in patients
with myocardial ischemia and heart failure. However, their usage
could exacerbate cardiovascular (through a negative inotropic
effect) and respiratory complications, mainly in elderly patients
(Rochon et al., 1999; Chaudhary et al., 2015). Consequently, a
pure bradycardic agent might be useful in conditions in which
beta-adrenergic blocker cannot be used due to their side effects.
In this regard, ivabradine—a novel selective inhibitor of HCN
channels—has emerged as a promising “pure” heart rate (HR)
lowering drug (DiFrancesco and Camm, 2004; Bucchi et al.,
2006).
To date, the mammalian genome encodes four HCN isoforms
(HCN1 to HCN4), which relate to ion conductivity, mainly
in the central nervous system and the heart (Notomi and
Shigemoto, 2004; Harzheim et al., 2008). HCN4, which has
been described as the main HCN channel of sinoatrial node,
and the prevalent isoform expressed in the heart conduction
system (Brioschi et al., 2009; Furst and D’Avanzo, 2015), is
the preferential target of ivabradine (Chaudhary et al., 2015).
In vitro studies have demonstrated that ivabradine specifically
blocks the HCN pore in a low-moderate concentration range
(Bucchi et al., 2002; DiFrancesco, 2010). It greatly inhibits the
hyperpolarization-active current (If) and reduces the firing rate
of the sinoatrial node cells at small concentrations, without
influencing other ion currents (calcium and potassium) (Bois
et al., 1996). Moreover, experimental and clinical studies have
corroborated the use of ivabradine as a favorable therapeutic
strategy, since they revealed no unwanted cardiovascular
outcome (negative inotropic or lusitropic effects), preserving
ventricular contractility (DiFrancesco and Camm, 2004; Sulfi and
Timmis, 2006). The lack of cardiovascular side effects and the
specificity of ivabradine on lowering heart rate provide relevant
advantages for its clinical usage. However, little is known about
the effects of ivabradine on the cardiovascular autonomic control.
HR, whose control is achieved through intrinsic and
extrinsic mechanisms, respectively, by If pacemaker current
of HCN channels and the autonomic nervous system (Verrier
and Tan, 2009), are determinants of myocardial oxygen
demand and may also affect myocardial perfusion. The
autonomic system, which exerts reflex and tonic control
over the cardiovascular homeostasis, influences the HCN
voltage-dependence, changing the diastolic depolarization and,
consequently, the HR (DiFrancesco, 1993). In this context,
knowledge concerning the effects of chronic treatment with
ivabradine on cardiovascular autonomic control has become
essential. A few reports have described some autonomic effects
of If blockers, including ivabradine, during acute endovenous
treatment (Barzilai and Jacob, 2015; Dias da Silva et al., 2015).
However, to our knowledge, no study has attempted to investigate
the chronic effects of ivabradine on reflex autonomic control
of HR and sympathetic nerve activity. Therefore, in the present
study we assessed, in rats, the effects of chronic treatment
with ivabradine on the cardiovascular autonomic modulation,
the cardiovascular reflexes regulation (baroreflex, Bezold-Jarish
reflex and chemoreflex) and tonic autonomic HR control, as well
as on the RSNA.
Featuring the effects of chronic treatment with ivabradine on
the HR, may provide a considerable in vivo understanding of
its effects on the cardiovascular autonomic system. Therefore,
improving our knowledge on the pharmacodynamics of this drug
and providing substantial outcomes for the clinical usage of
ivabradine as a cardiac medication.
MATERIALS AND METHODS
Experimental Model
Experiments were performed on male Wistar rats (300 ±
10 g), supplied by the Center of Animal Science of the Federal
University of Ouro Preto (UFOP). They were kept in grouped
cages (n = 3) on a 12 h light/dark cycle, at a controlled
room temperature (23◦C), with free access to commercial chow
and filtered water. Efforts were made to avoid any unnecessary
distress to the rats, in accordance to the Brazilian Council for
Animal Experimentation. All procedures were approved by the
institutional ethics committee for animal research of UFOP
(CEUA 2014/66; 2015/59), and were performed according to
the regulations set forth by the National Institutes of Health
Guidelines for the Care and Use of Laboratory Animals.
Experimental Preparation
Rats were divided in two treatment groups, respectively, vehicle
and ivabradine receiving intraperitoneal (i.p.) injections of
PBS (1mL/kg/day; single doses) or ivabradine (10mg/kg/day
or 2mg/kg/day; single doses) during 7 or 8 consecutive days
according to experimental design (detailed in Experimental
Design Section). On the 5th day of treatment, the animals were
submitted to surgical procedures, as described below.
Surgical Procedures Related to Experiment 1
Rats were anesthetized with ketamine and xylazine solution
(80mg/kg; 7mg/kg; i.m.). Polyethylene catheters were
placed into the femoral artery and vein, respectively,
for cardiovascular recordings and drugs infusion, which
have been described in detail elsewhere (Martins et al.,
2011). Prophylactic treatment with antibiotics [Veterinary
Pentabiotic—penicillin (benzatinbenzilpenicillin, procain
benzilpenicillin and potassicbenzilpenicillin), streptomicyn and
dihydrostreptomycin: 1mL/kg; i.m.] and anti-inflammatory
(Ketoprofen: 4mg/kg; i.m.) drugs were performed in order to
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prevent postsurgical infections and inflammation, respectively
(Silva et al., 2013). After 48 h of recovery from the anesthesia
and surgery, rats were conducted to experimental protocol
(Rodrigues-Barbosa et al., 2012).
Surgical Procedures Related to Experiment 2
Rats were anesthetized with urethane (1.2–1.4 g/kg, i.p. with
supplementary doses of 0.1 g/kg i.v., if required). The adequacy
of anesthesia was verified by the absence of the corneal reflex and
a withdrawal response to nociceptive stimulation of a hind paw.
A tracheotomy was performed to maintain and unobstructed
airway, and all the animals were allowed to breathe freely.
Polyethylene catheters were placed into the femoral artery and
vein, respectively, for pulsatile arterial pressure recording and
drug injections. The rat was mounted in a stereotaxic apparatus
and the left renal nerve was exposed and prepared as described
previously (Muller-Ribeiro et al., 2012; Xavier et al., 2014).
Briefly, the renal nerve was exposed from a retroperitoneal
approach. It was carefully separated from surrounding tissue
and placed on a silver bipolar recording electrode and immersed
in mineral oil for sympathetic nerve activity recording. The
signals from the recording electrode were amplified and filtered
(bandwidth 100–2000Hz). The signals were then digitized (1000
samples/s) and recorded using the PowerLab system. Chart
software was used to rectify and integrate the RSNA signals.
Experimental Design
As mentioned in the experimental preparation section, rats
were submitted to chronic treatment during 7 and 8 days, in
accordance to the previous literature (da Silva et al., 1994).
All experiments started only after stabilization of physiological
parameters for at least 30min.
Experiment 1: The Effects of Chronic Treatment with
Ivabradine (8 days) on Modulatory, Reflex and Tonic
Autonomic Control of Heart Rate (n = 14)
This experiment was conducted in non-anesthetized freely
moving rats (vehicle group: PBS 1mL/kg/day i.p.—single doses;
n = 6 and ivabradine group: 2mg/kg/day i.p.—single doses;
n = 8; both during 8 days), in order to test the effects of
ivabradine on the cardiovascular variability, reflex sensitivities
and tonic control of HR. In this experiment, we used 2mg/kg
of ivabradine, since higher doses evoked a severe bradycardia.
The adopted dose was based on previous studies (Dias da Silva
et al., 2015). On the 7th day of treatment, rats were submitted to
30min of basal period recording, which was used to quantify HR
and systolic arterial pressure (SAP) variability parameters in the
time—and the frequency-domain (spectral analysis), followed by
the assessment of cardiovascular reflexes and cardiac autonomic
tone. On the 8th day of treatment, rats were re-submitted to
30min of basal period, followed by the measurement of cardiac
autonomic tone, as will be detailed later.
In order to evaluate cardiovascular variability parameters,
mean values of SAP, mean arterial pressure (MAP), diastolic
arterial pressure (DAP), and pulse interval (PI) were calculated
for each 20–30-min period of recording. For the cardiovascular
variability study, the signals of arterial pressure (AP) were
processed using a software (PRE24 software, kindly provided by
Dr. Alberto Porta, University of Milan, Italy) to generate beat-
to-beat time series of PI, DAP, and SAP. The variance of these
values in each period was considered a variability index in the
time-domain. In order to minimize the potential influence of
the absolute numerical values on the calculation of variance, we
have also performed the calculation of the normalized variance,
which consisted in dividing each single PI, SAP, or DAP values
by the mean value of the entire respective time series and
multiplying the result for 100% (Sacha, 2014). Therefore, the
normalized variance (calculated from the adjusted time series
and expressed in %) is corrected for the mean value of the time
series. The variability of PI, DAP and SAP was also evaluated in
the frequency domain using an autoregressive spectral analysis
method. The theoretical and analytical proceedings are described
in previous studies (Malliani et al., 1991; TFESCNASPE,
1996). Briefly, beat by beat time series of PI, DAP, and SAP
were divided into serial segments of 300 beats, wherein all
successive segments were overlapped by 50% (150 beats) on
the previous segments (Welch’s method). Using stationary time
series segments, autoregressive parameters were estimated using
Levinson-Durbin’s method, and the model order was chosen
according to Akaike’s criteria (Rubini et al., 1993; TFESCNASPE,
1996). Then, on each individual stationary segment of 300
beats, spectral decomposition was performed using appropriate
autoregressive software. The normalization procedure, applied
only to the variability of the PI, was performed by dividing
the power of the low frequency component (low frequency—LF,
0.20–0.750Hz) or high frequency (high frequency—HF, 0.75–
3.00Hz) by total spectral power, which is subtracted from the
power of the very low frequency band (very low frequency—
VLF, 0.01 to 0.20Hz), and multiplying the result by 100 (Rubini
et al., 1993). The spectral parameters obtained for each individual
stationary segment of 300 beats were averaged, and the average
values resulting from 30min of recording were calculated for
each animal.
In order to assess the baroreflex sensitivity, we administered
intravenous bolus injection (i.v.) of phenylephrine (2, 4, and
8µg/kg) and sodium nitroprusside (4, 8, and 16µg/kg, i.v.)
for calculating the 1HR/1MAP index (Oliveira et al., 2005),
which was obtained through the mean of the three doses. We
also administered phenylbiguanide (1.25; 2.5 and 5µg/kg, i.v.)
and potassium cyanide (80 and 160µg/kg, i.v.) to evaluate,
respectively, the Bezold-Jarish reflex and chemoreflex sensitivities
(Penitente et al., 2007; Bezerra et al., 2011). All aforementioned
i.v. injections were performed every 5min. Subsequently, to
evaluate the ivabradine influence on the tonic autonomic
control of the heart, we also performed the sympathetic and
vagal autonomic blockade after propranolol (5mg/kg, i.v.)
and methylatropine (4mg/kg, i.v.) injections, respectively, to
calculate the sympathetic and vagal effects, as well as the intrinsic
HR and tonic sympathovagal index (Goldberger, 1999). The
autonomic blockers were administered in a random sequence
with a 15min interval between them, on the 7th and 8th days of
treatment. After double blockade, the cardiovascular recordings
lasted for 15min. Briefly, the sympathetic effect was considered
as the difference between the HR after sympathetic blockade
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and resting HR (Sympathetic effect = HR after sympathetic
blockade - resting HR). Vagal effect was calculated as the
difference between HR after vagal blockade and resting HR
(Vagal effect = HR after vagal blockade - resting HR). The tonic
sympathovagal index was obtained as the ratio between resting
and intrinsic HR, considering that the intrinsic HR (iHR) was
the HR obtained after double autonomic blockade (Goldberger,
1999).
Experiment 2: The Effects of Chronic Treatment with
Ivabradine (7 days) on Heart Rate (HR), Mean Arterial
Pressure (MAP) and Renal Sympathetic Nerve
Activity (RSNA) (n = 10)
This experiment was conducted in urethane-anesthetized rats
(vehicle group: PBS 1mL/kg/day i.p.; single doses; n = 5
and ivabradine group: 10mg/kg/day i.p.; single doses; n =
5, both during 7 days), in order to test the effects of
ivabradine on HR, MAP, and RSNA. The ivabradine dose was
chosen based on earlier studies (Du et al., 2004; Luszczki
et al., 2013). For this purpose, such parameters were recorded
during 60min. The RSNA signal was amplified (10 K), filtered
(100–1000Hz), displayed on an oscilloscope and monitored
via an audio-amplifier. The filtered nerve activity signal was
rectified, integrated (resetting every second), displayed online
and acquired using Powerlab 4/20 LabChart 7.1 (ADInstruments,
Sydney, Australia). All data were digitized at 1 kHz. The noise
of the recording system was determined post mortem (urethane:
0.5mL; i.v) and subtracted from the RSNA values obtained
during the experiment (Muller-Ribeiro et al., 2012; Xavier et al.,
2014). The quantitation of spikes/second was conducted using
a previously described methodology (Gomes da Silva et al.,
2012). Body temperature was monitored since the beginning of
surgical procedure using a rectal thermometer and maintained
in the range of 37–37.5◦C using a heating pad (Xavier et al.,
2014).
Statistical Analysis
Regarding Experiment 1, baseline values of HR and SAP
variability parameters were compared. In addition, for reflexes
and autonomic tone studies, baseline values of HR and MAP
were obtained by averaging the 1min-period that preceded
drugs injections. Maximum changes (mean ± SEM) were
calculated using the peak response after drugs injections (for
cardiovascular reflexes analysis) or using the last 1min-period
corresponding to each autonomic blockade recording (for
autonomic tone analysis). The effects between groups (ivabradine
2mg/kg vs. vehicle) were compared using Student’s unpaired
t-test.
In relation to the Experiment 2, data were obtained by
averaging the values of the whole recording. They were expressed
as absolute values and reported as mean ± SEM. The effects
between groups (ivabradine 10mg/kg vs. vehicle) were compared
using Student’s unpaired t-test.
Prism 5.0 (GraphPad Software, La Jolla, CA, USA) was
used to analyze all data. The significance level was set
at p< 0.05.
FIGURE 1 | Values of (A) resting heart rate (HR, bpm) and (B) mean
arterial pressure (MAP, mmHg) in non-anesthetized Wistar rats
submitted to vehicle (PBS 1mL/kg/day i.p.; single dose; n = 6) or
ivabradine (2mg/kg/day i.p.; single dose; n = 8) treatment during 8
days. Bars represent mean ± SEM. *p < 0.05, vehicle (VEH-black) vs.
ivabradine (IVA- White); Student’s unpaired t-test.
RESULTS
Experiment 1: Chronic Treatment with
Ivabradine (8 Days) Did Not Change
Cardiovascular Variability as Well as the
Reflex and Tonic Autonomic Control of
Heart Rate in Non-anesthetized Rats
As expected, compared with vehicle-treated group (VEH), the
ivabradine-treated rats (IVA: 2mg/kg/day; i.p.) presented lower
resting (VEH: 362± 16 bpm vs. IVA: 260± 14 bpm, p = 0.0005;
Figure 1A) and intrinsic HR (VEH: 369 ± 9 bpm vs. IVA: 326
± 11 bpm, p = 0.0146; Figure 3D). Ivabradine treatment also
decreased resting MAP (VEH: 115 ± 3mmHg vs. IVA: 102 ±
2mmHg, p = 0.0020; Figure 1B).
Heart rate variability analysis by means of spectral
autoregressive decomposition of pulse interval (PI) time-
series in all experimental groups is summarized in Table 1.
Treatment with ivabradine significantly increased variance and
absolute values of LF and HF spectral components, without any
changes in normalized LF and HF parameters and LF/HF ratio
in ivabradine-treated rats when compared to vehicle-treated
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TABLE 1 | Mean values (±SEM) of pulse interval (PI), variance and VLF, LF,
and HF spectral components of pulse interval variability in
non-anesthetized Wistar rats from vehicle or ivabradine-treated rats.
Vehicle Ivabradine
(n = 6) (n = 8)
PI (ms) 166.0±6.4 232.1±7.9*
Variance (ms2) 22.3±6.7 70.1±10.5*
Normalized Variance (%) 6.7±1.2 18.9±3.2*
VLF (ms2) 10.6±3.6 22.2±4.8
LF (ms2) 3.2±3.1 15.2±4.1*
LF (nu) 24.2±4.6 29.8±6.4
HF (ms2) 8.4±4.7 32.4±7.5*
HF (nu) 75.1±3.7 69.2±5.8
LF/HF 0.31±0.09 0.35±0.13
PI, Pulse interval; VLF, very low frequency component; LF, low frequency component; LF
(nu), LF in normalized units; HF, high frequency component; HF (nu), HF in normalized
units. *p < 0.05 vs. vehicle.
TABLE 2 | Mean values (±SEM) of systolic arterial pressure (SAP), variance
and VLF, LF and HF spectral components of arterial pressure variability in
non-anesthetized Wistar rats from vehicle or ivabradine-treated rats.
Vehicle Ivabradine
(n = 6) (n = 8)
SAP (mmHg) 142.2±3.4 128.5±3.1*
Variance (mmHg)2 15.3±4.1 17.6±6.2
Normalized Variance (%) 11.2±1.4 15.1±2.3
VLF (mmHg)2 5.4±0.7 6.1±1.6
LF (mmHg)2 6.2±1.5 6.8±2.0
HF (mmHg)2 3.3±2.0 4.1±1.8
LF/HF 1.9±0.8 1.6±1.8
SAP, Systolic arterial pressure; VLF, very low frequency component; LF, low frequency
component; HF, high frequency component. *p < 0.05 vs. vehicle.
animals (Table 1). Systolic arterial pressure variability analysis is
summarized in Table 2. Despite of the significantly lower values
of SAP, no changes in SAP variability parameters were observed
in ivabradine-treated rats when compared to vehicle-treated
animals (Table 2). The behavior of diastolic arterial pressure
variability was similar to the SAP variability (data not shown).
Regarding the possible influence of the chronic treatment
with ivabradine on HR baroreflex control, we administered
intravenous injection (i.v.) of phenylephrine (PHE: 2, 4,
and 8µg/kg) and sodium nitroprusside (SNP: 4, 8, and
16µg/kg, i.v.) to assess the baroreflex sensitivity. The baroreflex
bradycardic and tachycardic gains were calculated through
1HR/1MAP index. No changes were observed in bradycardic
(VEH:−2.7 ± 0.4 bpm/mmHg vs. IVA:−2.9 ± 0.8 bpm/mmHg,
p = 0.8025; Figure 2A) and tachycardic gains (VEH:−6.9 ±
0.6 bpm/mmHg vs. IVA:−7.7 ± 1.1 bpm/mmHg, p =
0.6432; Figure 2B) between groups. We also administered
phenylbiguanide (PBG: 1.25; 2.5 and 5µg/kg, i.v.) and potassium
cyanide (KCN: 80 and 160µg/kg, i.v.) to assess the Bezold-Jarish
reflex and chemoreflex regulation, respectively. The treatment
with ivabradine during 8 days did not modify the cardiovascular
responses to Bezold-Jarish reflex activation, since all PBG injected
doses induced similar hypotension and bradycardia in VEH and
IVA groups (1MAP: PBG 1.25−VEH:−4± 1mmHg vs. IVA:−7
± 2mmHg, p = 0.2525; PBG 2.5−VEH:−5.5 ± 2mmHg vs.
IVA:−10 ± 3mmHg, p = 0.2303; PBG 5−VEH:−5 ± 1mmHg
vs. IVA:−10 ± 3mmHg, p = 0.1318; Figure 2C); (1HR: PBG
1.25−VEH:−45 ± 14 bpm vs. IVA: −63 ± 20 bpm, p =
0.5; PBG 2.5−VEH:−143 ± 35 bpm vs. IVA:−124 ± 25 bpm,
p = 0.2848; PBG 5−VEH:−139 ± 25 bpm vs. IVA:−122 ±
20 bpm, p = 0.3199; Figure 2D). Similarly, the ivabradine
treatment did not change the chemoreflex responsiveness. The
amplitude of hypertensive and bradycardic responses evoked
by KCN injections were similar in both groups (1MAP: KCN
80−VEH: 14 ± 6mmHg vs. IVA: 16 ± 5mmHg, p = 0.4259;
KCN 160−VEH: 21 ± 4mmHg vs. IVA: 17 ± 4mmHg, p =
0.5162; Figure 2E); (1HR: KCN 80−VEH:−66 ± 23 bpm vs.
IVA:−92± 19 bpm, p = 0.2018;KCN 160−VEH:−87± 22 bpm
vs. IVA:−121± 15 bpm, p = 0.1087; Figure 2F).
In order to evaluate the influence of ivabradine chronic
treatment on the tonic autonomic control of the heart, we
performed the vagal and sympathetic autonomic blockade
through methylatropine (4mg/kg, i.v.) and propranolol
(5mg/kg, i.v.) injections, respectively, to calculate the vagal and
sympathetic effects, as well as the tonic sympathovagal index.
No differences on vagal (1HR; VEH: 96 ± 18 bpm vs. IVA:
86 ± 22 bpm, p = 0.3571; Figure 3A) neither on sympathetic
effects (1HR; VEH: −47 ± 11 bpm vs. IVA: −36 ± 13 bpm,
p = 0.2724; Figure 3B) were observed between VEH and IVA
groups. Additionally, the ivabradine treatment did not alter
the sympathovagal balance, expressed by tonic sympathovagal
index (VEH: 0.91 ± 0.02 vs. IVA: 0.88 ± 0.03, p = 0.3494;
Figure 3C).
Experiment 2: Chronic treatment with Ivabradine (7
days) Reduced Heart Rate (HR), Without Significant
Effects on Mean Arterial Pressure (MAP) and Renal
Sympathetic Nerve Activity (RSNA) in
Urethane-anesthetized Rats
Representative records (A,B) and changes in HR (C), MAP
(D) and RSNA (E) induced by the chronic treatment with
ivabradine were shown in Figure 4. Compared with vehicle
treatment, the ivabradine administration (10mg/kg/day; i.p.)
during 7 consecutive days markedly reduced resting HR (VEH:
364 ± 12 bpm vs. IVA: 207 ± 11 bpm, p < 0.0001; Figure 4C).
However, such ivabradine treatment did not change MAP (VEH:
70 ± 4 vs. IVA: 77 ± 6mmHg, p = 0.3293; Figure 4D) and
RSNA (VEH: 117 ± 16 vs. IVA: 120 ± 9 spikes/sec, p = 0.9100;
Figure 4E).
DISCUSSION
In this study, we evaluated the effects of chronic treatment with
ivabradine—a “pure” HR lowering drug which selectively inhibits
the pacemaker HCN channels—on the autonomic control of
the HR in rats. Our results showed that, in healthy animals, a
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FIGURE 2 | Effects of chronic treatment with ivabradine on the reflex control of the heart rate in non-anesthetized Wistar rats. (A) Baroreflex bradycardic
gain and (B) baroreflex tachycardic gain, respectively, induced by phenylephrine (PHE: 2, 4, and 8µg/kg) and sodium nitroprusside (SNP: 4, 8, and 16µg/kg, i.v.)
injections. Baroreflex gains were obtained by 1HR/1MAP index (bpm/mmHg), which was calculated through the mean of three used doses. Changes in mean arterial
pressure (MAP, mmHg) and heart rate (HR, bpm) induced by (C,D) phenylbiguanide (PBG: 1.25; 2.5, and 5µg/kg, i.v.) and (E,F) potassium cyanide (KCN: 80 and
160µg/kg, i.v.) injections were performed to assess the Bezold-Jarish reflex and chemoreflex regulation, respectively, in non-anesthetized Wistar rats submitted to
vehicle (PBS 1mL/kg/day i.p.; single dose; n = 6) or ivabradine (2mg/kg/day i.p.; single dose; n = 8) treatment during 8 days. Bars represent mean ± SEM of vehicle
(VEH—black) and ivabradine (IVA—white) groups. p > 0.05, VEH vs. IVA (Student’s unpaired t-test).
long-term ivabradine administration reduced resting HRwithout
promoting any change on the cardiovascular reflexes and tonic
autonomic regulation of the heart, as well as on RSNA. As
no study has investigated this set of variables to date, our
data provides new in vivo insights about the chronic effects of
ivabradine on the cardiovascular autonomic system.
Exploring whether chronic treatment with ivabradine could
influence the autonomic regulation of the HR, we assessed
its effects on the reflex and on the tonic autonomic control.
In the present investigation, performed in freely moving rats,
ivabradine treatment (2mg/kg/day) during 8 days induced a
significant reduction in resting and intrinsic HR. Furthermore,
it also significantly decreased resting MAP, which could be
ascribed to a cardiac output fall due to a marked ivabradine-
induced bradycardia. It is plausible to infer that, since we did not
observe any ivabradine-induced RSNA and autonomic changes,
which indirectly suggest no effect on the peripheral resistance.
The ivabradine-induced bradycardia (28%) was greater than that
achieved in other experimental (Dias da Silva et al., 2015) and
clinical studies (15–20%) (Fox et al., 2008; Swedberg et al.,
2010). The discrepancy between the bradycardia magnitudes may
be explained, at least, by two reasons. Firstly, the mentioned
experimental report was performed on anesthetized rats, which
were submitted to acute ivabradine injection (Dias da Silva
et al., 2015). Secondly, there is a plausible difference between
the pharmacodynamic of ivabradine in rats and humans, which
exhibit lower HR values. The ivabradine blockade is current-
dependent and favored by depolarization, when the drug
molecules are impelled to their intracellular binding site by the
inward flow of permeating cations (sodium and potassium).
In addition, ivabradine binds to HCN channels in open state,
whose configuration depends on the attachment of the cyclic
adenosine monophosphate (cAMP). Consequently, ivabradine
presents upper activity when cAMP levels are high, such as
in adrenergic stimulation that results in higher HR. It is a
particular property, which provides its strong use-dependent
action and suggests that its rate-reducing efficiency might be
enhanced at high rates (Bucchi et al., 2002; DiFrancesco, 2005),
as observed in non-anesthetized rats. Although, ivabradine-
induced bradycardia observed in our study was not comparable
to those considered appropriated to therapeutic action, it was
crucial for our objective to obtain a greater bradycardia, since it
assured a worst scenario for its potential influence on autonomic
system.
We also analyzed the effects of chronic treatment with
ivabradine on cardiovascular reflex control (baroreflex, Bezold-
Jarish reflex and chemoreflex). The ivabradine treatment did
not affect the bradycardic and tachycardic gains of baroreflex,
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FIGURE 3 | Effects of chronic treatment with ivabradine on the tonic
autonomic control of the heart rate in non-anesthetized Wistar rats. (A)
Vagal and (B) sympathetic effects were obtained, respectively, by the
difference between vagal blockade (by methylatropine: 4mg/kg, i.v.) or
sympathetic blockade (by propranolol: 5mg/kg, i.v.) and resting HR. (C)
Sympathovagal balance was expressed by the tonic sympathovagal index,
which is the ratio between resting and intrinsic HR. (D) Intrinsic HR (iHR, bpm)
—the HR was obtained after autonomic double blockade. All aforementioned
parameters were evaluated in non-anesthetized Wistar rats submitted to
vehicle (PBS 1mL/kg/day i.p.; single dose; n = 6) or ivabradine (2mg/kg/day
i.p.; single dose; n = 8) treatment during 8 days. Bars represent mean ± SEM
of vehicle (VEH—black) and ivabradine (IVA—white) groups. *p < 0.05, VEH
vs. IVA (Student’s unpaired t-test).
neither the hypotensive and bradycardic responses evoked by
Bezold-Jarish reflex activation, as well as the hypertensive and
bradycardic responses induced by peripheric chemoreceptors
stimulation. To our knowledge, it was the first time that these
reflexes were studied in non-anesthetized rats submitted to
long-term use of ivabradine. A few reports leading with this
subject investigated the acute intravenous injection effects of
HCN blockers in rats (Kruger et al., 2000; Dias da Silva et al.,
2015). One study, in which acute zatebradine i.v. injection was
conducted in non-anesthetized sham-rats, revealed an increase
in arterial baroreflex sensitivity (Kruger et al., 2000). However, a
recent study from our group performed in anesthetized rats, that
received acute ivabradine i.v. injection, showed that ivabradine
did not alter the baroreflex sensitivity (Dias da Silva et al., 2015).
As mentioned above, chronic treatment, during 7–8 days, could
permit a resetting of cardiovascular autonomic reflexes to a new
hemodynamic context.
In order to deepen the understanding about the influence of
chronic use of ivabradine on autonomic regulation of the HR,
we also evaluated its effects on modulatory and tonic autonomic
control. For that, we performed HR variability analysis, and
vagal and sympathetic autonomic blockade, respectively. We also
evaluated the tonic sympathovagal index, which is a validated
methodology to assess the vagal and sympathetic cardiac tonic
balance (Goldberger, 1999). Regarding to HR variability analysis,
we observed in ivabradine-treated animals a markedly higher
value of variance, a time–domain index, which was accompanied
to higher values in LF and HF spectral components, without
any changes in normalized LF and HF components, as well
as in LF/HF ratio. Even though, at the first glance, these
findings could suggest an increased sympathetic (higher LF
component) and parasympathetic modulation (higher variance
and HF component). The normalization procedure and LF/HF
ratio show a balanced autonomic modulation. As previously
reported by our group (Dias da Silva et al., 2015) and others
(Rocchetti et al., 2000; Zaza and Lombardi, 2001; Monfredi
et al., 2014), the increase in all spectral components (expressed
in absolute units) and in the variance (sum of the individual
spectral components) can be considered, since these parameters
are intrinsically dependent on mean interbeat interval (pulse
interval), which was directly increased by ivabradine more than
possible changes in the autonomic influences toward sinus node.
In fact, our results of autonomic blockade with atropine and
propranolol seem to reinforce this idea, since no differences were
observed on vagal and sympathetic effects. Additionally, the tonic
sympathovagal index was not affected by ivabradine treatment.
It was <1 in vehicle and ivabradine groups, indicating a vagal
dominance in both (Goldberger, 1999). Taken together, these
data suggest that, in rats, the sustained use of ivabradine did
not alter the autonomic balance to the heart. Despite of that,
as showed by Mangin et al. (1998), the intrinsic dependency
of variance and spectral parameters on mean HR does not
rule out the possibility that these parameters may be also
modulated by neural influences, which probably could be the
case under several conditions of real autonomic imbalance, as
observed in many cardiovascular disease conditions (Malliani
et al., 1991; TFESCNASPE, 1996; Schwartz and De Ferrari,
2011). Despite of a small decrease in arterial pressure, SAP
variability data did not show any difference between both vehicle
and ivabradine groups. LF component of SAP variability has
been considered an indirect marker of vascular sympathetic
modulation, suggesting that chronic treatment with ivabradine
does not change sympathetic activity not only to the heart but
also to the peripheral vessels. However, given the large standard
errors of means observed on SAP variability parameters, the lack
of differences between vehicle and ivabradine treatment should
be interpreted cautiously and not as a definitive statement that
ivabradine does not change arterial pressure variability. More
experiments with a higher number of cases in a near future
should be performed to clarify this issue.
In order to further understanding ivabradine actions on
sympathetic control, we assessed the sympathetic nervous
system responsiveness to long-term treatment with ivabradine
by a direct methodology. Thus, we analyzed the effects
of chronic injections of ivabradine (10mg/kg/day; during 7
days) on RSNA, as well as in HR and MAP in urethane-
anesthetized rats. Recordings of RSNA are technically more
amenable in anesthetized than in freely moving animals
(Xavier et al., 2014), however the cardiovascular autonomic
control is affected by anesthetics. Urethane presents minor
interference with autonomic activity, but reduces the sympathetic
tone whereas it seems to leave the parasympathetic tone
relatively intact (Shimokawa et al., 1998; Bencze et al.,
2013).Taking this into account, as Experiment 2 was performed
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FIGURE 4 | Effects of chronic treatment with ivabradine on heart rate, mean arterial pressure and renal sympathetic nerve activity in
urethane-anesthetized Wistar rats. (A) Representative records of vehicle (PBS 1mL/kg/day i.p.; single dose; n = 5) or (B) ivabradine-induced changes
(10mg/kg/day i.p.; single dose; n = 5) in heart rate (HR, bpm), mean arterial pressure (MAP, mmHg) and renal sympathetic nerve activity (RSNA, spikes/sec) after 7
days of treatment. Bars represent mean ± SEM of resting HR (C), MAP (D), and RSNA (E) in vehicle (VEH—black) and ivabradine (IVA—white) groups. *p < 0.05,
VEH vs. IVA (Student’s unpaired t-test).
under urethane-anesthesia, we used a ivabradine dose 5-fold
higher to that administered in Experiment 1 because it was
substantial to assure a enough severe scenario to evaluate
the potential influence of ivabradine on autonomic control.
Ivabradine treatment reduced restingHR, without affectingMAP,
corroborating previous studies (Du et al., 2004; Verrier et al.,
2014; Gent et al., 2015). Furthermore, it did not change RSNA.
RSNA is closely correlated with arterial pressure and is believed
to be a reliable indicator of overall sympathetic vasomotor
activity (Burgess et al., 1997). This finding is consistent with
the SAP and HR variabilities parameters observed in non-
anesthetized rats, strongly suggesting that long-term ivabradine
administration does not compromise the sympathetic autonomic
regulation. A recent study by our group showed that, in rats,
ivabradine-induced bradycardia was associated with increased
cardiac sympathetic nerve activity, resulting from baroreceptor
unloading (Dias da Silva et al., 2015). Additionally, another study
reported that, in sham-rats, zatebradine (another HCN blocker)
increases the heart rate variability—a marker of autonomic
modulation of HR (Kruger et al., 2000). However, such data
methodologically differs from ours in some aspects: (i) they
refer to acute i.v. injections while in our study the ivabradine
effects were assessed 7–8 days after continuous treatment, a time
frame long enough to induce baroreceptor resetting and, (ii) the
second report used a HCN blocker less specific than ivabradine.
Ivabradine, which is an open channel-required blocker, reaches
its binding site by entering in the HCN pore from an intracellular
side, being able to specifically block the pore channel in a low-
moderate concentration range (Bucchi et al., 2002).
Corroborating the widespread idea that ivabradine is a
promissor cardiac medication, three current clinical studies have
shown that acute treatment with ivabradine did not alter the
HR and blood pressure variabilities and baroreflex sensitivity,
suggesting no implications on the sympatho-vagal balance in
healthy men (Heusser et al., 2016; Schroeder et al., 2016) and
in postural tachycardia syndrome patients (Barzilai and Jacob,
2015). In addition, some studies have reported that ivabradine
exerts no side effects on the: (i) conductivity and refractoriness
(in atrium, atrioventricular node, His–Purkinje system and
ventricles), (ii) left ventricular ejection fraction, (iii) stroke
volume and (iv) some ECG measurements (corrected QT, PR,
and QRS intervals) (DiFrancesco and Camm, 2004), reinforcing
the advantage and viability of ivabradine use to the detriment
of others reducing HR drugs, such as beta-blockers. Blockade
of beta receptors, which are found throughout the heart, can
promote a beneficial reduction of HR, though it could trigger
side effects due to its presence in several organs, including in the
cardiovascular and respiratory systems (Tattersfield, 1991; Bois
et al., 1996; Sulfi and Timmis, 2006). Beta-blockers also slow the
If current via the reduction in sympathetic activity and cAMP
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formation, while ivabradine acts specifically inhibiting If current
(Sulfi and Timmis, 2006).
In accordance to all aforementioned, our data indicates that
long-term treatment with ivabradine, in healthy rats, reduces
the resting and intrisic heart rate, without compromising:
(i) baroreflex sensitivity, (ii) Bezold-Jarish reflex control, (iii)
chemoreflex resposiveness, (iv) BP and HR variabilities, (v)
vagal and sympathetic tones, (vi) tonic sympathovagal index
and (vii) RSNA. Characterizing the actions of chronic treatment
with ivabradine on the cardiovascular autonomic control in
rats can provide an additional understanding of its effects on
cardiovascular autonomic system, and then significantly improve
our knowledge to support the ivabradine clinical use.
AUTHOR CONTRIBUTIONS
FS drafted the work and substantially contributed to work
design, as well as, acquired, analyzed and interpreted the all
data. FP acquired the data and also substantially contributed
to work design and to analysis and interpretation of the all
data. FM substantially contributed to acquisition and analysis
of the RSNA data, HC substantially contributed to Bezold
Jarish reflex data acquisition. MF, RD, KC, GF, ET, and MS
substantially contributed to all data interpretation, NM, VD,
and DC designed the work, and substantially contributed
to analysis and interpretation of the all data. All authors
revised the work critically, approved the final version to
be published and declared accountable for all aspects of
the work.
FUNDING
This study was supported by the Conselho Nacional
de Desenvolvimento Científico e Tecnológico (CNPq,
grant #400851/2014-8 for VD), Coordenação de
Aperfeiçoamento de Pessoal de Nível Superior (CAPES),
Fundação de Amparo à Pesquisa de Minas Gerais (FAPEMIG),
Universidade Federal de Ouro Preto (UFOP) and Universidade
Federal do Triângulo Mineiro (UFTM), Brazil.
ACKNOWLEDGMENTS
The authors are grateful to Center of Science Animal/UFOP
for supplying the rats, to Milton Alexandre de Paula
and Marly de Lourdes Ferreira Lessa for technical
assistance.
REFERENCES
Barzilai, M., and Jacob, G. (2015). The effect of ivabradine on the heart
rate and sympathovagal balance in postural tachycardia syndrome
patients. Rambam Maimonides Med. J. 6:e0028. doi: 10.5041/RMMJ.
10213
Bencze, M., Behuliak, M., and Zicha, J. (2013). The impact of four different classes
of anesthetics on the mechanisms of blood pressure regulation in normotensive
and spontaneously hypertensive rats. Physiol. Res. 62, 471–478. Available online
at: http://www.biomed.cas.cz/physiolres/pdf/62/62_471.pdf
Bezerra, V. M., Xavier, C. H., de Menezes, R. C., Fontes, M. A., Cardoso,
L. M., Fernandes, L. G., et al. (2011). Bezold-Jarisch reflex in sino-
aortic denervated malnourished rats. Auton Neurosci. 162, 48–53. doi:
10.1016/j.autneu.2011.03.006
Bois, P., Bescond, J., Renaudon, B., and Lenfant, J. (1996). Mode of action of
bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells.
Br. J. Pharmacol. 118, 1051–1057.
Brioschi, C., Micheloni, S., Tellez, J. O., Pisoni, G., Longhi, R., Moroni, P.,
et al. (2009). Distribution of the pacemaker HCN4 channel mRNA and
protein in the rabbit sinoatrial node. J. Mol. Cell. Cardiol. 47, 221–227. doi:
10.1016/j.yjmcc.2009.04.009
Bucchi, A., Baruscotti, M., and DiFrancesco, D. (2002). Current-dependent block
of rabbit sino-atrial node I(f) channels by ivabradine. J. Gen. Physiol. 120, 1–13.
doi: 10.1085/jgp.20028593
Bucchi, A., Tognati, A., Milanesi, R., Baruscotti, M., and DiFrancesco, D.
(2006). Properties of ivabradine-induced block of HCN1 and HCN4
pacemaker channels. J. Physiol. 572, 335–346. doi: 10.1113/jphysiol.2005.
100776
Burgess, D. E., Hundley, J. C., Li, S. G., Randall, D. C., and Brown, D. R.
(1997). Multifiber renal SNA recordings predict mean arterial blood pressure
in unanesthetized rat. Am. J. Physiol. 273, R851–R857.
Chaudhary, R., Garg, J., Krishnamoorthy, P., Shah, N., Lanier, G., Martinez, M.W.,
et al. (2015). Ivabradine: heart failure and beyond. J. Cardiovasc. Pharmacol.
Ther. 21, 335–343. doi: 10.1177/1074248415624157
da Silva, V. J., da Silva, S. V., Salgado, M. C., and Salgado, H. C. (1994). Chronic
converting enzyme inhibition facilitates baroreceptor resetting to hypertensive
levels. Hypertension 23, I68–I172.
Dias da Silva, V. J., Tobaldini, E., Rocchetti, M., Wu, M. A., Malfatto, G., Montano,
N., et al. (2015). Modulation of sympathetic activity and heart rate variability
by ivabradine. Cardiovasc. Res. 108, 31–38. doi: 10.1093/cvr/cvv180
Diaz, A., Bourassa, M. G., Guertin, M. C., and Tardif, J. C. (2005). Long-
term prognostic value of resting heart rate in patients with suspected
or proven coronary artery disease. Eur. Heart J. 26, 967–974. doi:
10.1093/eurheartj/ehi190
DiFrancesco, D. (1993). Pacemaker mechanisms in cardiac tissue. Annu. Rev.
Physiol. 55, 455–472. doi: 10.1146/annurev.ph.55.030193.002323
DiFrancesco, D. (2005). Cardiac pacemaker I(f) current and its inhibition
by heart rate-reducing agents. Curr. Med. Res. Opin. 21, 1115–1122. doi:
10.1185/030079905X50543
DiFrancesco, D. (2010). Funny channel-based pacemaking. Heart Rhythm 7,
276–279. doi: 10.1016/j.hrthm.2009.10.030
DiFrancesco, D., and Camm, J. A. (2004). Heart rate lowering by specific and
selective I(f) current inhibition with ivabradine: a new therapeutic perspective
in cardiovascular disease. Drugs 64, 1757–1765. doi: 10.2165/00003495-
200464160-00003
Du, X.-J., Feng, X., Gao, X.-M., Tan, T. P., Kiriazis, H., and Dart, A. M.
(2004). If channel inhibitor ivabradine lowers heart rate in mice with
enhanced sympathoadrenergic activities. Br. J. Pharmacol. 142, 107–112. doi:
10.1038/sj.bjp.0705696
Fox, K., Ford, I., Steg, P. G., Tendera, M., Robertson, M., Ferrari, R., et al. (2008).
Heart rate as a prognostic risk factor in patients with coronary artery disease
and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis
of a randomised controlled trial. Lancet 372, 817–821. doi: 10.1016/S0140-
6736(08)61171-X
Furst, O., and D’Avanzo, N. (2015). Isoform dependent regulation of human HCN
channels by cholesterol. Sci. Rep. 5:14270. doi: 10.1038/srep14270
Gent, S., Kleinbongard, P., Dammann, P., Neuhauser, M., and Heusch, G. (2015).
Heart rate reduction and longevity in mice. Basic Res. Cardiol. 110, 2. doi:
10.1007/s00395-014-0460-7
Goldberger, J. J. (1999). Sympathovagal balance: how should we measure it? Am. J.
Physiol. 276, H1273–H1280.
Gomes da Silva, A. Q., Xavier, C. H., Campagnole-Santos, M. J., Caligiorne, S.
M., Baltatu, O. C., Bader, M., et al. (2012). Cardiovascular responses evoked
by activation or blockade of GABA(A) receptors in the hypothalamic PVN are
Frontiers in Physiology | www.frontiersin.org 9 July 2016 | Volume 7 | Article 305
Silva et al. Ivabradine Preserves the Cardiovascular Autonomic Control
attenuated in transgenic rats with low brain angiotensinogen. Brain Res. 1448,
101–110. doi: 10.1016/j.brainres.2012.02.021
Hall, A. S., and Palmer, S. (2008). The heart rate hypothesis: ready to be tested.
Heart 94, 561–565. doi: 10.1136/hrt.2007.118760
Harzheim, D., Pfeiffer, K. H., Fabritz, L., Kremmer, E., Buch, T., Waisman, A., et al.
(2008). Cardiac pacemaker function of HCN4 channels in mice is confined to
embryonic development and requires cyclic AMP. EMBO J. 27, 692–703. doi:
10.1038/emboj.2008.3
Heusser, K., Tank, J., Brinkmann, J., Schroeder, C., May, M., Großhennig, A., et al.
(2016). Preserved autonomic cardiovascular regulation with cardiac pacemaker
inhibition: a crossover trial using high-fidelity cardiovascular phenotyping.
J. Am. Heart Assoc. 5: e002674. doi: 10.1161/JAHA.115.002674
Kruger, C., Landerer, V., Zugck, C., Ehmke, H., Kubler, W., and Haass, M. (2000).
The bradycardic agent zatebradine enhances baroreflex sensitivity and heart
rate variability in rats early after myocardial infarction. Cardiovasc. Res. 45,
900–912. doi: 10.1016/S0008-6363(99)00405-8
Luszczki, J. J., Prystupa, A., Andres-Mach, M., Marzeda, E., and Florek-Luszczki,
M. (2013). Ivabradine (a hyperpolarization activated cyclic nucleotide-gated
channel blocker) elevates the threshold for maximal electroshock-induced
tonic seizures in mice. Pharmacol. Rep. 65, 1407–1414. doi: 10.1016/S1734-
1140(13)71500-7
Malliani, A., Pagani, M., Lombardi, F., and Cerutti, S. (1991). Cardiovascular
neural regulation explored in the frequency domain. Circulation 84, 482–492.
Mangin, L., Swynghedauw, B., Benis, A., Thibault, N., Lerebours, G., and Carre,
F. (1998). Relationships between heart rate and heart rate variability: study in
conscious rats. J. Cardiovasc. Pharmacol. 32, 601–607.
Martins, C. D., Chianca, D. A. Jr., Fernandes, L. G. (2011). Cardiac autonomic
balance in rats submitted to protein restriction after weaning. Clinical Exp.
Pharmacol. physiol. 38, 89–93. doi: 10.1111/j.1440-1681.2010.05468.x
Monfredi, O., Lyashkov, A. E., Johnsen, A. B., Inada, S., Schneider, H.,
Wang, R., et al. (2014). Biophysical characterization of the underappreciated
and important relationship between heart rate variability and heart
rate. Hypertension 64, 1334–1343. doi: 10.1161/HYPERTENSIONAHA.114.
03782
Muller-Ribeiro, F. C., Zaretsky, D. V., Zaretskaia, M. V., Santos, R. A., DiMicco,
J. A., and Fontes, M. A. (2012). Contribution of infralimbic cortex in the
cardiovascular response to acute stress. Am. J. Physiol. Regul. Integr. Comp.
Physiol. 303, R639–R650. doi: 10.1152/ajpregu.00573.2011
Notomi, T., and Shigemoto, R. (2004). Immunohistochemical localization of Ih
channel subunits, HCN1-4, in the rat brain. J. Comp. Neurol. 471, 241–276. doi:
10.1002/cne.11039
Oliveira, P. F., Dias da Silva, V. J., Salgado, M. C., Fazan, R. Jr., Aguiar, C. A., and
Salgado, H. C. (2005). Acute effect of amiodarone on cardiovascular reflexes of
normotensive and renal hypertensive rats. Braz. J. Med. Biol. Res. 38, 967–976.
doi: 10.1590/S0100-879X2005000600020
Penitente, A. R., Fernandes, L. G., Cardoso, L. M., Silva, M. E., Pedrosa,
M. L., Silva, A. L., et al. (2007). Malnutrition enhances cardiovascular
responses to chemoreflex activation in awake rats. Life Sci. 81, 609–614. doi:
10.1016/j.lfs.2007.07.006
Rocchetti, M., Malfatto, G., Lombardi, F., and Zaza, A. (2000). Role of the
input/output relation of sinoatrial myocytes in cholinergic modulation of heart
rate variability. J. Cardiovasc. Electrophysiol. 11, 522–530. doi: 10.1111/j.1540-
8167.2000.tb00005.x
Rochon, P. A., Anderson, G. M., Tu, J. V., Clark, J. P., Gurwitz, J. H., Szalai, J. P.,
et al. (1999). Use of beta-blocker therapy in older patients after acutemyocardial
infarction in Ontario. CMA J. 161, 1403–1408.
Rodrigues-Barbosa, M. C., Carneiro, C. M., de Oliveira, L. B., Silva, F. C. S., Xavier,
C. H., Fernandes, L. G., et al. (2012). Protein malnutrition modifies medullary
neuronal recruitment in response to intermittent stimulation of the baroreflex.
Brain Res. 1483, 20–30. doi: 10.1016/j.brainres.2012.08.019
Rubini, R., Porta, A., Baselli, G., Cerutti, S., and Paro, M. (1993). Power spectrum
analysis of cardiovascular variability monitored by telemetry in conscious
unrestrained rats. J. Auton. Nerv. Syst. 45, 181–190.
Sacha, J. (2014). Interaction between heart rate and heart rate variability. Ann.
Noninvasive Electrocardiol. 19, 207–216. doi: 10.1111/anec.12148
Schroeder, C., Heusser, K., Zoerner, A. A., Großhennig, A., Wenzel, D., May, M.,
et al. (2016). Pacemaker current inhibition in experimental human cardiac
sympathetic activation: a double-blind, randomized, crossover study. Clin.
Pharmacol. Ther. 95, 601–607. doi: 10.1038/clpt.2014.25
Schwartz, P. J., and De Ferrari, G. M. (2011). Sympathetic-parasympathetic
interaction in health and disease: abnormalities and relevance in heart failure.
Heart Fail. Rev. 16, 101–107. doi: 10.1007/s10741-010-9179-1
Shimokawa, A., Kunitake, T., Takasaki, M., and Kannan, H. (1998). Differential
effects of anesthetics on sympathetic nerve activity and arterial baroreceptor
reflex in chronically instrumented rats. J. Auton. Nerv. Syst. 72, 46–54.
Silva, F. C., Guidine, P. A., Ribeiro, M. F., Fernandes, L. G., Xavier, C. H., de
Menezes, R. C., et al. (2013). Malnutrition alters the cardiovascular responses
induced by central injection of tityustoxin in Fischer rats. Toxicon 76, 343–349.
doi: 10.1016/j.toxicon.2013.09.015
Sulfi, S., and Timmis, A. D. (2006). Ivabradine – the first selective sinus node
I(f) channel inhibitor in the treatment of stable angina. Int. J. Clin. Pract. 60,
222–228. doi: 10.1111/j.1742-1241.2006.00817.x
Swedberg, K., Komajda, M., Bohm, M., Borer, J. S., Ford, I., Dubost-
Brama, A., et al. (2010). Ivabradine and outcomes in chronic heart failure
(SHIFT): a randomised placebo-controlled study. Lancet 376, 875–885. doi:
10.1016/S0140-6736(10)61198-1
(TFESCNASPE) Task Force of the European Society of Cardiology and the
North American Society of Pacing and Electrophysiology (1996). Heart rate
variability: standards of measurement, physiological interpretation and clinical
use. Circulation 93, 1043–1065.
Tattersfield, A. E. (1991). Respiratory function in the elderly and the effects of beta
blockade. Cardiovasc. Drugs Ther. 6(Suppl. 4), 1229–1232.
Verrier, R. L., Bonatti, R., Silva, A. F., Batatinha, J. A., Nearing, B. D., Liu, G.,
et al. (2014). If inhibition in the atrioventricular node by ivabradine causes rate-
dependent slowing of conduction and reduces ventricular rate during atrial
fibrillation. Heart Rhythm 11, 2288–2296. doi: 10.1016/j.hrthm.2014.08.007
Verrier, R. L., and Tan, A. (2009). Heart rate, autonomic markers, and cardiac
mortality. Heart Rhythm 6, S68–S75. doi: 10.1016/j.hrthm.2009.07.017
Xavier, C. H., Ianzer, D., Lima, A. M., Marins, F. R., Pedrino, G. R., Vaz,
G., et al. (2014). Excitatory amino acid receptors mediate asymmetry and
lateralization in the descending cardiovascular pathways from the dorsomedial
hypothalamus. PLoS ONE 9:e112412. doi: 10.1371/journal.pone.01
12412
Zaza, A., and Lombardi, F. (2001). Autonomic indexes based on the analysis of
heart rate variability: a view from the sinus node. Cardiovasc. Res. 50, 434–442.
doi: 10.1016/S0008-6363(01)00240-1
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
The reviewer MF and handling Editor declared their shared affiliation, and
the handling Editor states that the process nevertheless met the standards of a
fair and objective review. The reviewer DC declared a shared affiliation, though
no other collaboration, with one of the author KC to the handling Editor, who
ensured that the process nevertheless met the standards of a fair and objective
review.
Copyright © 2016 Silva, Paiva, Müller-Ribeiro, Caldeira, Fontes, de Menezes, Casali,
Fortes, Tobaldini, Solbiati, Montano, Dias Da Silva and Chianca. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Physiology | www.frontiersin.org 10 July 2016 | Volume 7 | Article 305
